Akebia Therapeutics Inc (AKBA) Jumps 5.11% on February 12

Equities Staff |

Akebia Therapeutics Inc (AKBA) was among the biggest gainers on the Russell 2000 for Friday February 12 as the stock popped 5.11% to $7.61, representing a gain of $0.37 per share. Some 128,415 shares traded hands on 1,088 trades, compared with an average daily volume of 533,485 shares out of a total float of 30.63 million. The stock opened at $7.31 and traded with an intraday range of $7.75 to $7.12.

After today's gains, Akebia Therapeutics Inc reached a market cap of $233.11 million. Akebia Therapeutics Inc has had a trading range between $14.20 and $5.91 over the last year, and it had a 50-day SMA of $9.45 and a 200-day SMA of $9.14.

Akebia Therapeutics Inc is a biopharmaceutical company. It is engaged in the development of proprietary therapeutics based on hypoxia inducible factor, or HIF, biology and the commercialization of these products for patients with kidney disease.

Akebia Therapeutics Inc is based out of Cambridge, MA and has some 43 employees. Its CEO is John P. Butler.

For a complete fundamental analysis analysis of Akebia Therapeutics Inc , check out Equities.com’s Stock Valuation Analysis report for AKBA. To see the latest independent stock recommendations from Equities.com’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Equities.com. Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Comments

Emerging Growth

Immunovaccine Inc.

Immunovaccine Inc is clinical stage biopharmaceutical company. The Company develops products based on its proprietary vaccine enhancement platform in T cell activating therapies for cancer.

Private Markets

Santo Diablo Mezcal

Santo Diablo Mezcal has been created to capitalize on a boom sector of the beverage market currently full of many small unmemorable products by producing one sexy, household, easily recognizable…

Dropbox, Inc.

Dropbox is a service that allows their users to bring all photos, docs, and videos anywhere, and share them easily. Any file saved to Dropbox will automatically save to all…